Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for...
MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI
The University of Texas MD Anderson Cancer Center and Generate:Biomedicines today announced a strategic collaboration to jointly discover...
MD Anderson’s Hagop Kantarjian, M.D., awarded highest honor from American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) will present the 2023 David A. Karnofsky Memorial Award to Hagop Kantarjian, M.D...
MD Anderson Research Highlights for April 19, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include effective combination therapies for patients with BRAFV600E mutations,...
AACR: Single-cell study uncovers distinct immunosuppressive tumor microenvironment in brain metastases from kidney cancer
ABSTRACT: 5788
In a new study, researchers from The University of Texas MD Anderson Cancer Center created the largest single-cell atlas...
AACR: Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types
ABSTRACTS: CT016, CT018
Researchers from The University of Texas MD Anderson Cancer Center presented promising findings...
AACR: Mutations in three key genes associated with poor outcomes in lung cancer patients treated with KRAS G12C inhibitors
ABSTRACT: 3431
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that co-occurring mutations...
AACR: Novel allogeneic CAR T cell therapy delivers promising early results in patients with metastatic clear cell renal cell carcinoma
ABSTRACT: CT011
The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response...
AACR: YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers
ABSTRACT: CT006
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced...
MD Anderson Research Highlights AACR 2023 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Andy Futreal and Helen Piwnica-Worms elected Fellows of the AACR Academy
Two researchers from The University of Texas MD Anderson Cancer Center have been elected to the 2023 class of Fellows of the American Association...
MD Anderson applauds NCI’s National Cancer Plan
The University of Texas MD Anderson Cancer Center applauds the National Cancer Institute’s (NCI) National Cancer Plan and its framework...